STANLEY EMANUEL SHACKNEY
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD030341E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15243
Personal information
See more information about STANLEY EMANUEL SHACKNEY at radaris.comName
Address
Phone
331 Denniston Ave, Pittsburgh, PA 15206
11 Glen Ridge Ln, Mount Lebanon, PA 15243
11 Glen Rtdg, Pittsburgh, PA 15243
25 Mohawk Dr, Greensburg, PA 15601
Professional information
Dr. Stanley E Shackney, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
11 Glen Ridge Ln, Pittsburgh 15243
Certifications:
Internal Medicine, 1973, Medical Oncology, 1975
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
11 Glen Ridge Ln, Pittsburgh 15243
Allegheny General Hospital
320 East North Ave, Pittsburgh 15212
Allegheny General Hospital
320 East North Ave, Pittsburgh 15212
Education:
Medical School
Harvard Medical School
Graduated: 1964
Cincinnati Genl Hosp
Barnes-Jewish Hospital
Natl Cancer Inst
Harvard Medical School
Graduated: 1964
Cincinnati Genl Hosp
Barnes-Jewish Hospital
Natl Cancer Inst
Stanley Shackney, Pittsburgh PA
Work:
Allegheny General Hospital
320 E North Ave, Pittsburgh, PA 15212
320 E North Ave, Pittsburgh, PA 15212
Stanley Shackney
Location:
Greater Pittsburgh Area
Industry:
Biotechnology
Composite Profiles Of Cell Antigens And Target Signal Transduction Proteins For Analysis And Clinical Management Of Hematologic Cancers
US Patent:
2010026, Oct 14, 2010
Filed:
Jan 29, 2010
Appl. No.:
12/696702
Inventors:
Charles GOOLSBY - Winfield IL, US
T. Vincent Shankey - Miami FL, US
David Hedley - Toronto, CA
James Jacobberger - Chesterland OH, US
Stanley Shackney - Pittsburgh PA, US
T. Vincent Shankey - Miami FL, US
David Hedley - Toronto, CA
James Jacobberger - Chesterland OH, US
Stanley Shackney - Pittsburgh PA, US
Assignee:
Beckman Coulter, Inc. - Brea CA
International Classification:
G01N 33/574
US Classification:
435 723
Abstract:
The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Composite Profiles Of Cell Antigens And Target Signal Transduction Proteins For Analysis And Clinical Management Of Hematologic Cancers
US Patent:
2007010, May 10, 2007
Filed:
Nov 4, 2005
Appl. No.:
11/267948
Inventors:
Charles Goolsby - Winfield IL, US
T. Shankey - Miami FL, US
David Hedley - Toronto, CA
James Jacobberger - Chesterland OH, US
Stanley Shackney - Pittsburgh PA, US
T. Shankey - Miami FL, US
David Hedley - Toronto, CA
James Jacobberger - Chesterland OH, US
Stanley Shackney - Pittsburgh PA, US
International Classification:
G01N 33/574
US Classification:
435007230
Abstract:
The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Methods For Identification Of Tumor Phenotype And Treatment
US Patent:
2012002, Feb 2, 2012
Filed:
Nov 13, 2009
Appl. No.:
13/126023
Inventors:
Stanley E. Shackney - Pittsburgh PA, US
Assignee:
Intelligent Oncotherapeutics, Inc. - Pittsburgh PA
International Classification:
A61K 38/17, C07D 403/14, A61K 31/506, C07F 9/6512, A61K 31/675, C07D 401/12, A61K 31/454, C07D 413/12, A61K 31/5377, C07D 487/04, A61K 31/55, C07D 403/04, A61K 31/497, C07K 14/47, C07C 43/23, A61K 31/085, C40B 60/12, A61P 35/00, G06F 19/00, C40B 30/04
US Classification:
514 192, 506 9, 544295, 51425219, 544244, 514 80, 546201, 514323, 544119, 5142345, 540578, 514215, 544405, 51425505, 530324, 568652, 514720, 530350, 506 39, 702 19
Abstract:
The disclosure relates to methods for identifying a tumor as an E2F-responsive gene over-expressing (ERGO) tumor, methods of determining the likelihood that an ERGO tumor patient will survive to a future date, methods of treating an ERGO tumor in a patient, and methods of selecting patients diagnosed as ERGO tumor prostate cancer patients for aggressive clinical treatment. The methods of the disclosure are applicable to ERGO tumors present in different human organs and tissues such as breast, lung, thyroid, ovary, and prostate.
Cell Aggregate Correction
US Patent:
2004025, Dec 16, 2004
Filed:
Jun 13, 2003
Appl. No.:
10/461018
Inventors:
Stanley Shackney - Pittsburgh PA, US
Charles Smith - Pittsburgh PA, US
Agnese Pollice - Pittsburgh PA, US
Kathryn Brown - Eighty Four PA, US
Deborah Kociban - Pittsburgh PA, US
Charles Smith - Pittsburgh PA, US
Agnese Pollice - Pittsburgh PA, US
Kathryn Brown - Eighty Four PA, US
Deborah Kociban - Pittsburgh PA, US
Assignee:
Allegheny-Singer Research Institute
International Classification:
G01N033/48
US Classification:
436/063000, 422/073000
Abstract:
An apparatus for correcting for cell aggregates in a cell suspension from patients. The apparatus includes a laser cytometry scanning mechanism for scanning cells of a sample of a cell suspension to obtain data about the samples patients. The apparatus includes a memory for storing the data, the memory in communication with the scanning mechanism patients. The apparatus includes a computer for identifying in the data cell aggregates in the samples from the samples that have been scanned with an APT function, the computer in communication with the memory. A method for correcting for cell aggregates in a cell suspension from patients with an APT function. A method for correcting for cell aggregates in a cell suspension from patients with up to 98.6% accuracy. A computer readable medium.